Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins
Source abstract
Abstract
Various targeted protein degradation (TPD) approaches have been developed to overcome the limitations of traditional drug in eliminating pathogenic proteins by exploiting either the proteasomal or lysosomal pathway. However, there is still a lack of design strategies for TPD that utilize two distinct pathways to achieve the degradation of membrane and cytoplasmic proteins. Here, we develop a Nano-Targeting Chimera (Nano-APTAC), which is engineered by covalently attaching the protein-targeting aptamer to graphene oxide (GO) via the amide linkage, to hijack the autophagy-lysosome and ubiquitin-proteasome systems for targeted degradation of membrane and cytoplasmic proteins respectively. In contrast, a mixture of GO and aptamers without covalent interaction has no effect on protein degradation. Furthermore, the in vivo experiments demonstrate the efficacy of Nano-APTACs in depleting targeted proteins and inhibiting tumor growth. The work provides a versatile programmability platform, employing two distinct degradation systems to facilitate personalized design for the degradation of proteins regardless of their localization on the membrane or cytoplasm, and offering potential therapeutic benefits. STATEMENT OF SIGNIFICANCE: GO and aptamers have been combined for various applications. However, the utilization of this combination in TPD remains unknown. In this study, we found that the Nano-APTAC platform, constructed by covalently linking GO-aptamer chimera (not a simple mixture), can utilize autophagy-lysosome system and ubiquitin-proteasome system to degrade membrane and cytoplasmic proteins, respectively. The types of aptamers significantly influence the intracellular behavior of the chimeras, resulting in distinct subcellular localization and guiding the chimera to select specific degradation systems for protein removal. The Nano-APTAC's mode of action extremely expands the range of targeted proteins, prevents overload in specific degradation systems caused by excessive usage, and provides an exceptional level of adaptability in meeting diverse treatment requirements.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Targeted protein degradation as a powerful research tool in basic biology and drug target discovery10.1038/s41594-020-0438-0 ↗
2. Opportunities and challenges of protein-based targeted protein degradation10.1039/D3SC02361C ↗
3. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives10.1038/s41392-021-00572-w ↗
4. PROTACs: past, present and future10.1039/D2CS00193D ↗
5. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently10.1038/s41422-021-00533-6 ↗
6. Chasing molecular glue degraders: screening approaches10.1039/D2CS00197G ↗
7. A method for the acute and rapid degradation of endogenous proteins10.1016/j.cell.2017.10.033 ↗
8. The dTAG system for immediate and target-specific protein degradation10.1038/s41589-018-0021-8 ↗
9. SNIPERs-hijacking IAP activity to induce protein degradation10.1016/j.ddtec.2018.12.002 ↗
10. Lysosome-targeting chimaeras for degradation of extracellular proteins10.1038/s41586-020-2545-9 ↗
11. Targeted degradation of SNCA/α-synuclein aggregates in neurodegeneration using the AUTOTAC chemical platform10.1080/15548627.2023.2274711 ↗
12. Crosstalk and interplay between the ubiquitin-proteasome system and autophagy10.14348/molcells.2017.0115 ↗
13. Targeted protein degradation: mechanisms, strategies and application10.1038/s41392-022-00966-4 ↗
14. Role of protein degradation systems in colorectal cancer10.1038/s41420-023-01781-8 ↗
15. Nano-PROTACs: state of the art and perspectives10.1039/D3NR06059D ↗
16. Nano-LYTACs for degradation of membrane proteins and inhibition of CD24/Siglec-10 signaling pathway
17. Functional groups in graphene oxide10.1039/D2CP04082D ↗
18. Graphene and graphene oxide with anticancer applications: challenges and future perspectives10.1002/mco2.118 ↗
19. MMP9-responsive graphene oxide quantum dot-based Nano-in-Micro drug delivery system for combinatorial therapy of choroidal neovascularization10.1002/smll.202207335 ↗
20. Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML cells10.1038/s41467-022-33410-w ↗
21. Graphene-based materials for tissue engineering10.1016/j.addr.2016.03.007 ↗
22. Fluorescent biosensors enabled by graphene and graphene oxide10.1016/j.bios.2016.07.030 ↗
23. Carbon-based antiviral nanomaterials: graphene, C-dots, and fullerenes. A perspective10.1039/D0SC02658A ↗
24. First-in-human controlled inhalation of thin graphene oxide nanosheets to study acute cardiorespiratory responses10.1038/s41565-023-01572-3 ↗
25. Tissue distribution and urinary excretion of intravenously administered chemically functionalized graphene oxide sheets10.1039/C5SC00114E ↗
26. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
27. Development of DNA aptamers using Cell-SELEX10.1038/nprot.2010.66 ↗
28. Aptamer-based targeted protein degradation10.1021/acsnano.2c10379 ↗
29. Chemical tailoring of aptamer glues with significantly enhanced recognition ability for targeted membrane protein degradation10.1021/acsnano.3c04457 ↗
30. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes10.1002/anie.202102170 ↗
31. A DNA aptamer to c-Met inhibits cancer cell migration10.1039/C4CC06016D ↗
32. Quantification of activated NF-kappaB/RelA complexes using ssDNA aptamer affinity-stable isotope dilution-selected reaction monitoring-mass spectrometry10.1074/mcp.M111.008771 ↗
33. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy10.1038/s41568-018-0002-y ↗
34. Autophagy and ubiquitin-proteasome system10.1007/978-981-15-0602-4_25 ↗
35. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1)10.1080/15548627.2020.1797280 ↗
36. Autophagy-mediated clearance of ubiquitinated mutant huntingtin by graphene oxide10.1039/C6NR07255K ↗
37. Autophagy induction by trehalose counteracts cellular prion infection10.4161/auto.5.3.7662 ↗
38. Methods in mammalian autophagy research10.1016/j.cell.2010.01.028 ↗
39. Cytochalasins inhibit nuclei-induced actin polymerization by blocking filament elongation10.1083/jcb.84.2.455 ↗
40. Effects of Na+/H+ exchanger inhibitors on subcellular localisation of endocytic organelles and intracellular dynamics of protein transduction domains HIV-TAT peptide and octaarginine10.1016/j.jconrel.2006.07.009 ↗
41. Tyrosine phosphorylation of caveolin-1 in the endothelium10.1006/excr.1999.4652 ↗
42. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains10.1083/jcb.141.4.905 ↗
43. The role of the lateral dimension of graphene oxide in the regulation of cellular responses10.1016/j.biomaterials.2012.02.021 ↗
44. Two birds with one stone: guanidyl carbon dots with enhanced antioxidative and lipolytic functions in metabolic associated fatty liver10.1002/adfm.202406096 ↗
45. Neuron-targeted caveolin-1 protein enhances signaling and promotes arborization of primary neurons10.1074/jbc.M111.255976 ↗
46. Direct visualization of epithelial microvilli biogenesis10.1016/j.cub.2021.04.012 ↗
47. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance10.1080/15548627.2019.1580105 ↗
48. Requirement of the NF-kappaB subunit p65/RelA for K-ras-induced lung tumorigenesis10.1158/0008-5472.CAN-09-4290 ↗
49. Aptamer-based optical manipulation of protein subcellular localization in cells10.1038/s41467-020-15113-2 ↗
50. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation10.1016/j.cell.2007.10.009 ↗
51. A Stk4-Foxp3-NF-κb p65 transcriptional complex promotes T(reg) cell activation and homeostasis10.1126/sciimmunol.abl8357 ↗
52. PPARγ is an E3 ligase that induces the degradation of nfκb/p6510.1038/ncomms2270 ↗
53. Simulation and analysis of cellular internalization pathways and membrane perturbation for graphene nanosheets10.1016/j.biomaterials.2014.03.087 ↗
54. Antibody targeting of E3 ubiquitin ligases for receptor degradation10.1038/s41586-022-05235-6 ↗
55. Targeted protein degradation: from mechanisms to clinic10.1038/s41580-024-00729-9 ↗
56. The targeted protein degradation landscape
57. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy10.1038/s41392-024-01983-1 ↗
58. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer10.1002/anie.202107347 ↗
59. Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy10.1039/D3SC04249A ↗
60. 2D graphene oxide–aptamer conjugate materials for cancer diagnosis10.1038/s41699-021-00202-7 ↗
61. Graphene oxide and fluorescent aptamer based novel biosensor for detection of 25-hydroxyvitamin D(3)10.1038/s41598-021-02837-4 ↗
62. Covalently synthesized graphene oxide-aptamer nanosheets for efficient visible-light photocatalysis of nucleic acids and proteins of viruses10.1016/j.carbon.2012.02.038 ↗
63. Targeted protein degradation via cellular trafficking of nanoparticles
64. The protein corona from nanomedicine to environmental science10.1038/s41578-023-00552-2 ↗
65. Post-translational modifications of p65: state of the art
66. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress10.3390/cells11050851 ↗
67. Two-dimensional nanomaterials: a critical review of recent progress, properties, applications, and future directions